Status:
UNKNOWN
Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder
Lead Sponsor:
DDC Clinic - Center for Special Needs Children
Conditions:
GM3 Synthase Deficiency
Eligibility:
All Genders
Up to 20 years
Phase:
NA
Brief Summary
The purpose of this pilot project is to see if a supplemental form of dietary gangliosides can serve as a potential treatment for the rare metabolic condition called ganglioside GM3 synthase deficienc...
Eligibility Criteria
Inclusion
- Clinical diagnosis of GM3 synthase deficiency
Exclusion
- \-
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02234024
Start Date
January 1 2014
End Date
December 1 2020
Last Update
February 7 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.